H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant volatility, with ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

EyePoint Pharmaceuticals, Inc.’s EYPT share price has dipped by 15.13%, which has investors questioning if this is right time to buy.

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the ...